Recently, the National Healthcare Security Administration issued the "Several Measures to Support the High Quality Development of Innovative Drugs", which clarifies the full chain support for the development of innovative drugs from research and development, admission, payment, etc. In this context, cell therapy, as a highly breakthrough innovative therapy in the field of biomedicine, is expected to further enhance the accessibility and affordability of its products.

The Measures propose to encourage innovative drugs to conduct real-world research and link research results with medical insurance admission and renewal, promoting the application of real-world data in medical insurance admission. Of the 91 new drugs newly included in the medical insurance catalog in 2024, 33 were approved, launched, and included in the catalog that year, and innovative drugs are accelerating their integration into the medical insurance system. The clinical data accumulated through real-world research can more comprehensively verify the efficacy and safety of products, providing key basis for medical insurance decision-making. The recent symposium held by the National Healthcare Security Administration also clarified the attitude of supporting innovation, emphasizing the importance of scientifically evaluating the comprehensive value and high-quality evidence of innovative products.

In the field of cell therapy, taking CAR-T therapy as an example, Fosun Carey focuses on the field of tumor cell immunotherapy. Its product Yikaida was launched in China in June 2021 and is the first CAR-T cell therapy product in the country, achieving a breakthrough from "0" to "1" in this field. Up to now, Yikaida has benefited over 1000 patients with large B-cell lymphoma, and its extensive clinical application has accumulated rich experience in its use.

Real world research data in China shows that the best response rate (bORR) of Yikaida is 83.1%, and the best complete response rate (bCR) is 67.2%. These clinical practice data not only verify the efficacy of the product, but also provide value support for the medical insurance negotiations of such innovative drugs.

The Measures also optimized the renewal rules for innovative drugs, providing more lenient price reduction limits for innovative drugs with new indications, and providing policy guarantees for enterprises to continue research and development. In June 2023, Yikaida's new indication (adult large B-cell lymphoma that is ineffective in first-line immunotherapy or recurs within 12 months after first-line immunotherapy) was approved for marketing. It is the only CAR-T product in China with randomized controlled clinical trial evidence, fully verifying its effectiveness and safety. Currently, the expansion of new indications is still being promoted.

Innovation in payment models is an important link in improving the accessibility and affordability of innovative drugs, and is also a direction encouraged by the National Healthcare Security Administration. Yikaida's treatment network has covered more than 200 high standard treatment centers in 28 provinces, autonomous regions, and municipalities across the country, and has been included in over 110 urban welfare insurance and more than 80 commercial health insurance projects.

In the practice of Huimin Insurance, Shanghai's "Shanghai Huibao" has included Yikaida in the special drug protection catalog for four consecutive years, and insured patients who meet the indications can receive a maximum reimbursement of 500000 yuan for drug expenses. Over the past three years, more than 80 lymphoma patients have received treatment claims from Yikaida through "Shanghai Huibao", with a total compensation of over 40 million yuan, effectively improving treatment accessibility and bringing hope to patients.

After the first product of Fosun Carey was launched, it actively participated in the construction of the national multi-level medical security system, deeply integrated into the Huimin Insurance and commercial health insurance projects, and accumulated full process experience from product design, market promotion to compensation in high-value innovative drug commercial insurance applications, forming a practical model of CAR-T diversified payment. Local governments often use CAR-T compensation cases as a typical example to expand the influence of Huimin Insurance and Commercial Insurance. As a common product of Commercial Insurance, Yikaida helps attract more people to apply for insurance. This model not only reduces the burden of patients, but also plays a positive role in the optimization and sustainable development of China's innovative drug payment system.

Fosun Carey continues to explore and play an active role in the field of CAR-T cell therapy in China. Since its establishment in 2017, it has introduced internationally leading CAR-T cell therapy technology into China and achieved localized production, launching the first CAR-T cell therapy drug approved for market in China. During the process, Fosun Carey actively collaborated with government departments, participated in the formulation and improvement of regulatory regulations related to cell therapy, and promoted the standardized development of the industry. At the same time, it has participated in the development and implementation of multiple CAR-T industry guidelines, promoting the operation experience of CAR-T therapy that meets international high standards in China, significantly improving the standardization level of CAR-T therapy in our country.